IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma
Ibrain · 2024-03 · 10 (1) · 19-33
DOI: 10.1002/ibra.12150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ibrain, online erschienen am 11.03.2024. Verfasst von Ning Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology Affiliated Hospital of Guangdong Medical University Zhanjiang Guangdong China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Glioma, a malignant brain tumor originating from neural glial cells, presents significant treatment challenges. However, the underlying mechanisms of glioma development are not fully understood, and effective targets are lacking. This study provides insights into the role of insulin‐like growth factor 2 messenger RNA‐binding protein 2 (IGF2BP2) in glioma progression and its therapeutic potential. Our analysis illustrated that elevated IGF2BP2 expression associated with significantly shorter survival among patients with low‐grade glioma (LGG) in The Cancer Genome Atlas (TCGA) database. IGF2BP2 depletion led to compromised cell viability, G0/G1 phase arrest, and reduced colony‐formation ability. Furthermore, ultrastructural analysis and mCherry‐GFP‐LC3 reporter assay revealed an increased abundance of autophagosomes upon IGF2BP2 knockdown. Western blot analysis corroborated these findings by showing reduced p62 levels coupled with increased LC3‐ІІ/LC3‐I ratio upon IGF2BP2 knockdown. A multicolor immunohistochemistry assay demonstrated the positive correlation between IGF2BP2 and p62 expression in glioma patient samples. Additionally, our analysis suggested a link between IGF2BP2 expression and drug‐resistant markers in TCGA‐LGG samples, and Cell Counting Kit‐8 cell viability assay revealed that knockdown of IGF2BP2 sensitized cells to temozolomide treatment. This comprehensive exploration unveils the role of IGF2BP2 in glioma progression, shedding light on autophagy modulation and chemosensitization strategies for glioma therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology Affiliated Hospital of Guangdong Medical University Zhanjiang Guangdong China.
- The Marine Biomedical Research Institute Guangdong Medical University Zhanjiang China.
- Department of Obstetrics and Gynecology Affiliated Hospital of Guangdong Medical University Zhanjiang Guangdong China.
- Department of Neurosurgery, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
ORCID-Profile: Qingyu Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Li, N., Deng, L., Zhang, Y., Tang, X., Lei, B., & Zhang, Q. (2024). IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma. Ibrain, 10(1), 19-33. https://doi.org/10.1002/ibra.12150
Vancouver
Li N, Deng L, Zhang Y, Tang X, Lei B, Zhang Q. IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma. Ibrain. 2024;10(1):19-33. doi:10.1002/ibra.12150
BibTeX
@article{Li2024,
author = {Li, Ning and Deng, Limei and Zhang, Yuming and Tang, Xilian and Lei, Bingxi and Zhang, Qingyu},
title = {IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma},
journal = {Ibrain},
year = {2024},
volume = {10},
number = {1},
pages = {19--33},
doi = {10.1002/ibra.12150}
}
EUVIMED